NCT03695757View on ClinicalTrials.gov

Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 6, 2018

Primary Completion Date

January 26, 2021

Study Completion Date

March 24, 2021

Conditions
Immunotherapy
Interventions
BIOLOGICAL

Part A) Healthy subjects

Part A) Autologous total IgG 50mg will be administered to the healthy subjects by intramuscular injections, twice a week for 4 weeks (total 8 injections).

BIOLOGICAL

Part B) Advanced solid tumor

Part B) Autologous total IgG 50mg will be administered to the patients with advanced solid tumor by intramuscular injection, twice a week for 4 weeks (total 8 injections).

Trial Locations (1)

16499

Ajou university hosiptal, Suwon

All Listed Sponsors
lead

Ajou University School of Medicine

OTHER

NCT03695757 - Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG | Biotech Hunter | Biotech Hunter